141 related articles for article (PubMed ID: 29100982)
1. Thermodynamics of cooperative binding of FAD to human NQO1: Implications to understanding cofactor-dependent function and stability of the flavoproteome.
Clavería-Gimeno R; Velazquez-Campoy A; Pey AL
Arch Biochem Biophys; 2017 Dec; 636():17-27. PubMed ID: 29100982
[TBL] [Abstract][Full Text] [Related]
2. A mechanism for cancer-associated inactivation of NQO1 due to P187S and its reactivation by the consensus mutation H80R.
Muñoz IG; Morel B; Medina-Carmona E; Pey AL
FEBS Lett; 2017 Sep; 591(18):2826-2835. PubMed ID: 28771686
[TBL] [Abstract][Full Text] [Related]
3. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.
Pey AL; Megarity CF; Timson DJ
Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30518535
[TBL] [Abstract][Full Text] [Related]
4. Phosphorylation compromises FAD binding and intracellular stability of wild-type and cancer-associated NQO1: Insights into flavo-proteome stability.
Medina-Carmona E; Rizzuti B; Martín-Escolano R; Pacheco-García JL; Mesa-Torres N; Neira JL; Guzzi R; Pey AL
Int J Biol Macromol; 2019 Mar; 125():1275-1288. PubMed ID: 30243998
[TBL] [Abstract][Full Text] [Related]
5. Anion-specific interaction with human NQO1 inhibits flavin binding.
Pey AL
Int J Biol Macromol; 2019 Apr; 126():1223-1233. PubMed ID: 30615965
[TBL] [Abstract][Full Text] [Related]
6. Conformational dynamics is key to understanding loss-of-function of NQO1 cancer-associated polymorphisms and its correction by pharmacological ligands.
Medina-Carmona E; Palomino-Morales RJ; Fuchs JE; Padín-Gonzalez E; Mesa-Torres N; Salido E; Timson DJ; Pey AL
Sci Rep; 2016 Feb; 6():20331. PubMed ID: 26838129
[TBL] [Abstract][Full Text] [Related]
7. NQO1: A target for the treatment of cancer and neurological diseases, and a model to understand loss of function disease mechanisms.
Beaver SK; Mesa-Torres N; Pey AL; Timson DJ
Biochim Biophys Acta Proteins Proteom; 2019; 1867(7-8):663-676. PubMed ID: 31091472
[TBL] [Abstract][Full Text] [Related]
8. A mutually inhibitory feedback loop between the 20S proteasome and its regulator, NQO1.
Moscovitz O; Tsvetkov P; Hazan N; Michaelevski I; Keisar H; Ben-Nissan G; Shaul Y; Sharon M
Mol Cell; 2012 Jul; 47(1):76-86. PubMed ID: 22793692
[TBL] [Abstract][Full Text] [Related]
9. Site-to-site interdomain communication may mediate different loss-of-function mechanisms in a cancer-associated NQO1 polymorphism.
Medina-Carmona E; Neira JL; Salido E; Fuchs JE; Palomino-Morales R; Timson DJ; Pey AL
Sci Rep; 2017 Mar; 7():44532. PubMed ID: 28291250
[TBL] [Abstract][Full Text] [Related]
10. Collapse of the native structure caused by a single amino acid exchange in human NAD(P)H:quinone oxidoreductase(1.).
Lienhart WD; Gudipati V; Uhl MK; Binter A; Pulido SA; Saf R; Zangger K; Gruber K; Macheroux P
FEBS J; 2014 Oct; 281(20):4691-4704. PubMed ID: 25143260
[TBL] [Abstract][Full Text] [Related]
11. FAD-deficient P187S mutation of NAD(P)H:quinone oxidoreductase 1 (NQO1*2) binds and accelerates β-amyloid aggregation.
Panja S; Siegel D; Camandola S; de Cabo R; Ross D; Mallela KMG
Biosci Rep; 2022 Nov; 42(11):. PubMed ID: 36281795
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of the pleiotropic and specific phenotypic consequences of missense mutations in the multifunctional NAD(P)H:quinone oxidoreductase 1 and their pharmacological rescue.
Pacheco-Garcia JL; Anoz-Carbonell E; Vankova P; Kannan A; Palomino-Morales R; Mesa-Torres N; Salido E; Man P; Medina M; Naganathan AN; Pey AL
Redox Biol; 2021 Oct; 46():102112. PubMed ID: 34537677
[TBL] [Abstract][Full Text] [Related]
13. A small molecule chaperone rescues the stability and activity of a cancer-associated variant of NAD(P)H:quinone oxidoreductase 1 in vitro.
Strandback E; Lienhart WD; Hromic-Jahjefendic A; Bourgeois B; Högler A; Waltenstorfer D; Winkler A; Zangger K; Madl T; Gruber K; Macheroux P
FEBS Lett; 2020 Feb; 594(3):424-438. PubMed ID: 31605637
[TBL] [Abstract][Full Text] [Related]
14. Different phenotypic outcome due to site-specific phosphorylation in the cancer-associated NQO1 enzyme studied by phosphomimetic mutations.
Pacheco-Garcia JL; Anoz-Carbonell E; Loginov DS; Vankova P; Salido E; Man P; Medina M; Palomino-Morales R; Pey AL
Arch Biochem Biophys; 2022 Oct; 729():109392. PubMed ID: 36096178
[TBL] [Abstract][Full Text] [Related]
15. A Dynamic Core in Human NQO1 Controls the Functional and Stability Effects of Ligand Binding and Their Communication across the Enzyme Dimer.
Vankova P; Salido E; Timson DJ; Man P; Pey AL
Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31726777
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of NAD(P)H:quinone reductase: Ab initio studies of reduced flavin.
Cavelier G; Amzel LM
Proteins; 2001 Jun; 43(4):420-32. PubMed ID: 11340659
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated variants of human NQO1: impacts on inhibitor binding and cooperativity.
Megarity CF; Timson DJ
Biosci Rep; 2019 Sep; 39(9):. PubMed ID: 31431515
[TBL] [Abstract][Full Text] [Related]
18. Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase).
Zhao Q; Yang XL; Holtzclaw WD; Talalay P
Proc Natl Acad Sci U S A; 1997 Mar; 94(5):1669-74. PubMed ID: 9050836
[TBL] [Abstract][Full Text] [Related]
19. Negative Cooperativity in NAD(P)H Quinone Oxidoreductase 1 (NQO1).
Megarity CF; Abdel-Aal Bettley H; Caraher MC; Scott KA; Whitehead RC; Jowitt TA; Gutierrez A; Bryce RA; Nolan KA; Stratford IJ; Timson DJ
Chembiochem; 2019 Nov; 20(22):2841-2849. PubMed ID: 31165578
[TBL] [Abstract][Full Text] [Related]
20. Crystal structure of human quinone reductase type 2, a metalloflavoprotein.
Foster CE; Bianchet MA; Talalay P; Zhao Q; Amzel LM
Biochemistry; 1999 Aug; 38(31):9881-6. PubMed ID: 10433694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
